Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).

The patients in our study were nonetheless older, had worse performance status, a poor Charlson Comorbidity Index and were for most of them refractory to their previous treatment line thus explaining part of the lower ORR and CR rates in our cohort. Efficacy Patients received a median of 3.2 cycles (1-19 cycles), Figure 1A. One patient received whole brain radiotherapy consolidation after obtaining a partial response under treatment. All patients had relapsed (n = 6) or refractory (n = 16) disease, after a median of two lines of therapy (range, 1-3). [Extracted from the article]